Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation
Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu · 2026
Read Efficacy and safety of immune checkpoint inhibitors combined with TKIs for recurrent or metastatic cervical cancer with PIK3CA mutation by Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0350571.txt.
Description
Chang and five co-authors published a 2026 PLOS ONE study on hard-to-treat cervical cancer. The cancer had come back or spread to other parts of the body. The team tested the safety and effect of pairing immune checkpoint inhibitors with a class of drugs called TKIs. All patients carried a gene change named PIK3CA. Pairing drug types is a common hope when single drugs stop working.
Catalog record
| CREATOR | Lele Chang, Yaxin Kang, Mingxuan Zhu, Jing Liu, Chunyan Lan, Qin Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35122 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |